Kelly L Matson
Overview
Explore the profile of Kelly L Matson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matson K, Horton E, Capino A
J Pediatr Pharmacol Ther
. 2024 Oct;
29(5):550-553.
PMID: 39411409
Approximately 14.7 million US children aged 2 to 19 years are obese. This creates significant challenges to dosing medications that are primarily weight based (mg/kg) and in predicting pharmacokinetics parameters...
2.
Matson K, Fenn Iii N
Am J Health Syst Pharm
. 2024 Aug;
PMID: 39150883
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are...
3.
Lawal O, Aronow H, Hume A, Shobayo F, Matson K, Barbour M, et al.
Res Pract Thromb Haemost
. 2024 Jan;
8(1):102293.
PMID: 38268519
Background: Little to no data exist to guide treatment decision in patients with venous thromboembolism (VTE) and chronic liver disease. Objectives: To assess the effectiveness and safety of direct oral...
4.
Lawal O, Aronow H, Shobayo F, Hume A, Taveira T, Matson K, et al.
Circulation
. 2023 Feb;
147(10):782-794.
PMID: 36762560
Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease is unclear. Methods: We conducted...
5.
Nori P, Apisarnthanarak A, Bailey P, Langford B, MacMurray L, Marra A, et al.
Antimicrob Steward Healthc Epidemiol
. 2023 Jan;
3(1):e10.
PMID: 36714297
No abstract available.
6.
Marra A, Apisarnthanarak A, Simonsen K, Matson K, Bailey P, Sreeramoju P, et al.
Antimicrob Steward Healthc Epidemiol
. 2022 Dec;
2(1):e130.
PMID: 36483444
No abstract available.
7.
Langford B, Matson K, Eljaaly K, Apisarnthanarak A, Bailey P, MacMurray L, et al.
Antimicrob Steward Healthc Epidemiol
. 2022 Nov;
2(1):e187.
PMID: 36425221
One fundamental strategy to address the public health threat of antimicrobial resistance (AMR) is improved awareness among the public, prescribers, and policy makers with the aim of engaging these groups...
8.
Leiss M, Wangu Z, Bratberg J, Matson K
J Am Pharm Assoc (2003)
. 2022 Jun;
62(6):1860-1864.
PMID: 35690564
Background: Sexually transmitted infections (STIs) in the United States are at an all-time high. Expedited partner therapy (EPT) has been endorsed by the Centers for Disease Control and Prevention to...
9.
Higgins T, Menditto M, Katartzis S, Matson K
J Pediatr Pharmacol Ther
. 2022 Mar;
27(3):206-213.
PMID: 35350156
Sickle cell disease is a chronic and life-limiting disorder. Approximately 100,000 Americans are affected with sickle cell disease with most being African Americans. Newborn screening for sickle cell is available...
10.
Patry E, Upadhyay R, Bratberg J, Buchanan A, Matson K
R I Med J (2013)
. 2022 Jan;
105(1):20-25.
PMID: 35081184
Objective: To understand adolescent substance use and its known risk factors at the local and state level; to inform the development of future programs to reduce substance misuse among adolescents....